Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Mesa, 2016, Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 14, 1572, 10.6004/jnccn.2016.0169 Tefferi, 2005, bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment, Mayo Clin Proc, 80, 1220, 10.4065/80.9.1220 Tyner, 2010, CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms, Blood, 115, 5323, 10.1182/blood-2009-05-223727 Pardanani, 2009, CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients, Leukemia, 23, 1441, 10.1038/leu.2009.50 Asshoff, 2017, Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents, Blood, 129, 1823, 10.1182/blood-2016-09-740092 Pardanani, 2013, Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis, Leukemia, 27, 1322, 10.1038/leu.2013.71 Gupta, 2017, A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis, Haematologica, 102, 94, 10.3324/haematol.2016.148924 Tefferi, 2007, Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel, Blood, 110, 1092, 10.1182/blood-2007-04-083501 Barosi, 2008, Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment, Leukemia, 22, 437, 10.1038/sj.leu.2404914 Passamonti, 2010, A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment), Blood, 115, 1703, 10.1182/blood-2009-09-245837 Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014 Tefferi, 2013, Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report, Blood, 122, 1395, 10.1182/blood-2013-03-488098 Harrison, 2012, JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis, N Engl J Med, 366, 787, 10.1056/NEJMoa1110556 Xin, 2013, Dose-response analyses of momelotinib (CYT387), a JAK1 and JAK2 inhibitor, from a phase I/II study (CCL09101) in treatment of myelofibrosis, Blood, 122, 1590, 10.1182/blood.V122.21.1590.1590 Mesa, 2017, SIMPLIFY 1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naïve patients with myelofibrosis, J Clin Oncol, 35, 3844, 10.1200/JCO.2017.73.4418